| MOLECULAR CLASSIFICATION OF GASTRIC CANCER
Traditionally, the majority of gastric adenocarcinomas have been classified into two distinct histological subtypes based on Lauren's classification: intestinal-type and diffuse-type. The intestinal-type is the end-result of an inflammatory process that progresses from chronic gastritis to atrophic gastritis leading to intestinal metaplasia and dysplasia, whereas the diffuse-type is often associated with genetic abnormalities.
Recent molecular profiling studies have permitted the transition from traditional histological classification systems to molecularly based classification schemes. The landmark TCGA study examined 295 gastric cancer tumours using six different molecular analysis platforms encompassing DNA, RNA and protein assays and proposed a novel molecular characterization defined by four genomic subtypes: EpsteinBarr virus (EBV)-positive, microsatellite unstable (MSI), genomically stable (GS) and chromosomal instability (CIN).
8 EBV-positive tumours, which represent 9%-10% of gastric adenocarcinomas, harbour high levels of non-silent PI3KCA mutations (80%), extreme DNA hypermethylation, mutations in PTEN, SMADA, CDKN2A, ARIDA (55%) and BCOR (23%) and amplification of JAK2, ERBB2, PD-L1 and PD-L, suggesting that PI3K, JAK2 and immune checkpoint inhibitors could constitute valuable therapeutic options for the treatment of this tumour subtype.
8-12
Microsatellite unstable tumours (22%) are prevalent in women and older patients, exhibit elevated levels of microsatellite instability without major chromosomal abnormalities and strongly correlate with MLH1 promoter hypermethylation as well as recurrent mutations in PIK3CA, ERBB3, ERBB2 and epidermal growth factor receptor (EGFR) but lack targetable amplifications. 8, 9, 12, 13 GS tumours (20%), associated with diffuse-type adenocarcinomas, are diagnosed in younger patients and enriched with recurrent CDH1 (37%), RHOA (15%) and inactivating ARID1A mutations. Fusions involving the RHO-family GTPase-activating proteins CLDN18 and ARHGAP26 were also observed and their chimeric products could impact RHOA regulation.
Finally the chromosomal unstable (CIN) subtype accounts for 50% of GC tumours and correlates with extensive aneuploidy, TP53 mutations (71%) and RTK-RAS amplification affecting EGFR, ERBB2, ERBB3, VEGFA, FGFR2, Met, NRAS/KRAS, JAK2, CD274, PDCD1LG2
and PIK3CA. 8, 9, 11, 12 This in-depth analysis has elucidated the distinct genomic landscape of each GC molecular subtype, delineating specific mutational axes amenable to targeted molecular inhibition in different patient subsets. These advances have enabled extensive clinical trials investigating potential therapies, leading to the implementation of gamechanging therapeutic regimens and ongoing randomized trials of novel targeting compounds.
| KINASES AS TARGETS OF CANCER THERAPIES
Kinases constitute one of the largest families of proteins encoded by the human genome, with 518 kinase sequences confirmed so far. 6, 14 Based on their substrate preferences, kinases can be classified as serine-threonine kinases (STKs), which phosphorylate serinethreonine residues (400 members) or protein tyrosine kinases (PTKs), which phosphorylate tyrosine residues on downstream substrates (90 members). 7, 15 The elucidation of the first kinase signalling cascade involving protein kinase A (PKA) in the 1960s marked a milestone in the field, 14, 16 followed by Varmus and Bishop's breakthrough discovery that protein kinases can act as oncogenes, which received the 1989 Nobel Prize in Physiology.
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As systematic profiling studies revealed, protein and lipid kinases constitute critical and ubiquitous drivers of neoplastic disease and have generated tremendous research efforts aimed at designing selective inhibitors that antagonize them. The most common example is the small-molecule inhibitor imatinib, which targets the constitutively active mutant kinase BCR-ABL, the hallmark oncogene for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). 7, 18 Imatinib obtained FDA approval in 2001 and its success story established the paradigm for pharmaceutical development in the post-genomic translational era, centred on the identification of an aberrant tumour-specific kinase followed by the design of a specific inhibitor that targets this kinase, compound optimization and clinical testing. 7 Various classes of therapeutic drugs exist, including monoclonal antibodies and small-molecule kinase inhibitors. 
| Monoclonal antibodies

| MOLECULAR TARGETED AGENTS IN GC CLINICAL TRIAL
| Her2 blockade
The clinical success of trastuzumab and ramucirumab has prompted the investigation of other molecular agents such as small-molecule kinase inhibitors that target a plethora of oncogenic kinase drivers (EGFR, PI3K/AKT/mTOR or c-Met). For instance, the phase III LOGIC trial investigated the efficacy of lapatanib, an orally active dual tyrosine kinase inhibitor of EGFR and Her2, as a first-line therapy in combination with capecitabine and oxaliplatin in patients with Her2+
advanced GC but did not report any significant beneficial effect on median OS. 40 The Tytan trial, which investigated the addition of lapatanib to paclitaxel in the second-line setting in an Asian population, yielded similarly negative results. 41 In contrast, a phase II trial evaluating the inclusion of pertuzamab in a trastuzamab, capecitabine and cisplatin regimen in patients with Her2+ advanced GC achieved promising results, warranting the selection of pertuzamab for a phase III trial. 42 A phase II study assessing the benefit of adding T-DM1 to capecitabine in Her2+ advanced GC (clinicaltrials.org NCT01702558)
is currently underway while a phase III trial is evaluating the benefit of administering T-DM1 in association with taxane (clinicaltrials.gov NCT01641939).
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| EGFR blockade
Epidermal growth factor receptor is overexpressed in 2.3%-40% of 
| VEGFR blockade
Vascular endothelial growth factor is overexpressed in up to 60%
of GC and correlates with tumour aggressiveness, recurrence and advanced stage due to increased vascularization and angiogenesis. 9, 44 While ramucirumab was successfully incorporated into treatment strategies, the anti-VEGFR monoclonal antibody bevacizumab did not achieve the same success. The phase III AVAGAST study comparing bevacizumab addition to chemotherapy alone showed no median OS Another phase I/II trial is testing dovitinib in combination with docetaxel as a second-line therapy irrespective of FGFR2 status. 9, 12 Alternatively, combination therapy using FGFR and/or VEGFR and immune checkpoint inhibitors could constitute a promising strategy for cancer patients. 
| Fibroblast growth factor receptor blockade
| c-Met blockade
Mesenchymal-epithelial transition (Met) receptor is amplified in 2%-23% of GC and correlates with poor prognosis. 
| IMMUNOTHERAPY
Immunotherapy, which purports to harness the immune system to combat tumours, has emerged as a true paradigm changer in a number of cancers and was designated the 2013 breakthrough of the year by Science. 72 Immune-based strategies against cancer are based on 'immunization'. 73 They act by inducing effective tumour-specific immunity in order to bypass immunological tolerance to the tumour and reinstate anti-tumour immunity. 74 The therapeutic potential of 
| CONCLUSION
The molecular genotyping revolution has refined our understanding of gastric cancer and heralded the age of genome-guided targeted therapies. Kinase receptors are among the most frequently altered oncogenes in GC, rendering them key disease biomarkers and attractive drug targets. The availability of rapid diagnostic platforms, such as the novel NanoString-based multigene assay which analyzes EGFR, Her2
and MET status in GC patients, 91 facilitates the diagnosis and selection of effective molecular therapies. Despite these advances, the OS rate remains poor, especially since most cases are diagnosed at an advanced stage, which affects patient prognosis. The disparate results of clinical trials investigating kinase inhibitors and/or immunotherapy agents for GC treatment highlight the need for studies in biomarkerenriched populations and novel powerful inhibitors that improve therapeutic outcomes in patients. 
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